Similarly, in cross-sectional studies involving patients with heart failure, aortic stenosis, coronary artery disease and atrial fibrillation, the use of ACEi or ARBs did not affect plasma ACE2 activity in comparison with untreated patients [61–63]. Here, ACE2 is linked to aortic stenosis.